Biktarvy
Gilead’s Biktarvy proves non-inferior to standard care for HIV in Black and African American patients
October 22, 2020Research and Development Biktarvy, Gilead, HIV, pharma
Gilead has revealed promising new Phase 3 data reinforcing the non-inferiority of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg) compared to …
Gilead’s Biktarvy maintains HIV suppression for 48 weeks in children and adolescents
March 7, 2019Research and Development Biktarvy, Gilead, HIV, pharma
Gilead has lifted the curtain on new Phase 2/3 efficacy data for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 …
European Commission greenlights Gilead’s Biktarvy for HIV-1
June 25, 2018Sales and Marketing Biktarvy, EU, Europe, European Commission, HIV, HIV-1, pharma
Good news for Gilead and HIV patients across the European Union today as the prominent pharma firm announced that its …
Switching to Gilead’s Biktarvy proves non-inferior in HIV patients
March 6, 2018Manufacturing and Production, Research and Development Biktarvy, Gilead, HIV, pharma
Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir …
FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit
February 8, 2018Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma
Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
